Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 9;290(16):10447–10459. doi: 10.1074/jbc.M114.609230

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 3. — HMW-FGF-2 and cAMP activate integrative nuclear FGFR1 signaling pathway. A, effect of the chimeric FGFR1/FGFR4 construct on LWM-FGF-2 (25 ng/ml) stimulation of FGF-23 promoter activity in MC3T3-E1 osteoblasts. B, effect of the FGFR1 (SP−/NLS) mutant (0.25 μg) on LWM-FGF-2 (100 ng/ml) stimulation of FGF-23 promoter activity in MC3T3-E1 osteoblasts. C and D, co-transfection of HMW-FGF-2 (0.25 μg) stimulates FGF-23 promoter activity in both human and mouse osteoblast cells, whereas FSK (10 μm) alone shows little effect. Combination of HMW-FGF-2 and FSK enhances FGF-23 promoter activity by more than 5-fold as compared with controls. E and F, dose-dependent up-regulation of FGF-23 promoter activity by HMW-FGF-2 with fixed FSK (10 μm). G and H, dose-dependent up-regulation of FGF-23 promoter activity by FSK with fixed HMW-FGF-2 (0.25 μg). Data are expressed as the mean ± S.D. from three independent experiments. Values sharing the same superscript in different groups are not significantly different. *, p < 0.05; **, p < 0.01 versus control vector group, respectively.